Skip to search formSkip to main contentSkip to account menu

ErbB-2 Inhibitor ARRY-380

Known as: ONT-380 
An orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

ARRY-380
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A randomized study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated HER2-pos. metastatic breast cancer: HER2CLIMB
2017
2017
Abstract P1-12-04: Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in patients (pts) with HER2+ breast cancer brain metastases
Background: Brain metastases remain an important cause of death for pts with advanced HER2+ BC. ONT-380 is an oral, potent and… 
Review
2017
Review
2017
Abstract CT055: A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2…
Background: Tucatinib (ONT-380) is a highly selective small molecule inhibitor of HER2 kinase with nanomolar potency. Unlike dual… 
2016
2016
Abstract P4-14-19: ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets)
Background: The risk of CNS involvement in patients with HER2+ metastatic breast cancer (MBC) is high. The natural history of… 
2016
2016
Abstract P4-14-20: A phase 1b study of ONT 380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+ metastatic breast cancer (MBC)
Background: ONT 380 is a potent HER2 selective tyrosine kinase inhibitor with minimal EGFR-like side effects. Preclinical studies… 
2015
2015
ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets).
612 Background: Up to half of pts with HER2+ metastatic breast cancer (MBC) will develop CNS mets. Surgery and/or radiation… 
2015
2015
Phase 1b study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line + treatment of HER2+ metastatic breast cancer (MBC).
602 Background: ONT-380, a potent, highly selective, small molecule inhibitor of HER2, was associated with clinical benefit and… 
2015
2015
Abstract P4-15-08: A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+ metastatic breast cancer (MBC)
Background: ONT-380 (also known as ARRY-380) is a potent, selective small molecule inhibitor of HER2 with 500-fold selectivity… 
2014
2014
Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in participants with brain metastases from HER2+ breast cancer.
TPS660 Background: Central nervous system (CNS) metastases remain an important cause of morbidity and death for patients… 
2014
2014
A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+ metastatic breast cancer (MBC).
TPS662 Background: ONT-380 is a selective small molecule inhibitor of HER2 kinase with nanomolar potency. Unlike dual HER2/EGFR… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)